Quarterly ResultAug 6, 2026, 07:08 AM
Avalo Therapeutics Q2 2026 Results; $472.2M Cash, Runway into 2029
AI Summary
Avalo Therapeutics reported its second quarter 2026 financial results, with a net loss of $36.4 million and increased R&D and G&A expenses. Despite the loss, the company announced a strong cash position of $472.2 million as of June 30, 2026, providing an expected cash runway into 2029. Key business updates include plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in the first half of 2027 and the expansion of its pipeline with AVTX-010, targeting an IND submission in the first half of 2027. The company also appointed Ron Philip to its Board of Directors.
Key Highlights
- Cash, cash equivalents, and investments totaled $472.2 million as of June 30, 2026.
- Expected cash runway extends into 2029.
- Q2 2026 net loss was $36.4 million, compared to $20.8 million in Q2 2025.
- Research and development expenses rose to $23.4 million in Q2 2026.
- General and administrative expenses increased to $8.1 million in Q2 2026.
- Plans to initiate registrational Phase 3 for abdakibart in HS in H1 2027.
- IND submission for AVTX-010, a new anti-IL-1β antibody, planned for H1 2027.
- Ron Philip appointed to the Board of Directors.
Price Impact
More from AVTX